Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05190770 · ClinicalTrials.gov registry record · Phase 2
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT05190770: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05190770 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05190770, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is find out whether Oleogel-S10 is an effective treatment for radiation dermatitis when it is used in combination with a standard wound treatment cream called triamcinolone. Oleogel-S10 has shortened the healing time for other types of skin wounds such as burns. Triamcinolone is a cream that is frequently used to treat moderate to severe skin conditions such as skin irritation caused by poison ivy, eczema, sunburn, and rashes.
Interventions
- DRUG Triamcinolone Acetonide
- DRUG Oleogel-S10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-12-15 |
| Est. Completion | 2024-08-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05190770
The ClinicalTrials.gov registry entry for NCT05190770 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Triamcinolone Acetonide is the first listed.
NCT05190770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05190770 about?
NCT05190770 is a clinical study titled "A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer". The purpose of this study is find out whether Oleogel-S10 is an effective treatment for radiation dermatitis when it is used in combination with a standard wound treatment cream called triamcinolone. Oleogel-S10 has shortened the healing time for other types of skin wounds such as burns. Triamcinolo...
What is the current status of trial NCT05190770?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2021-12-15. Estimated completion is 2024-08-27.
What interventions are being tested in trial NCT05190770?
The interventions under investigation include: Triamcinolone Acetonide (DRUG), Oleogel-S10 (DRUG).
Who is sponsoring clinical trial NCT05190770?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.